Ignite Creation Date:
2024-05-05 @ 7:48 PM
Last Modification Date:
2024-10-26 @ 9:54 AM
Study NCT ID:
NCT00748371
Status:
TERMINATED
Last Update Posted:
2017-04-12
First Post:
2008-09-05
Brief Title:
Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration
Sponsor:
Vanderbilt University
Organization:
Vanderbilt University Medical Center
Study Overview
Official Title:
Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration
Status:
TERMINATED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Funding issue
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Aspirin has shown to be beneficial to some patients with certain diseases such as coronary artery disease or stroke We are investigating how aspirin works on regulating platelets and thromboxane over time at different doses We hope to find the best dose of aspirin andor other medications to help people who are at risk for heart attack or stroke
Detailed Description:
he purpose of the study is to better understand the mechanism for failure of daily aspirin administration to prevent cardiovascular events in some at risk individuals We seek to describe the effect of chronic aspirin administration at varying doses on platelet aggregation This will help to define mechanisms for aspirin failure and to pursue possible alternative therapies in patients who fail to respond to aspirin therapy
We hypothesize that 1 inhibition by aspirin ASA of ex vivo-induced platelet aggregation varies in a predictable time and dose dependent manner 2 thromboxane and prostacyclin production is inhibited by ASA in a dose-dependent manner and remains relatively constant over time once maximal inhibition has occurred and 3 granule secretion by platelets during induced aggregation is inhibited by aspirin acutely but this effect does not persist during chronic administration at high doses
We hypothesize that 1 inhibition by aspirin ASA of ex vivo-induced platelet aggregation varies in a predictable time and dose dependent manner 2 thromboxane and prostacyclin production is inhibited by ASA in a dose-dependent manner and remains relatively constant over time once maximal inhibition has occurred and 3 granule secretion by platelets during induced aggregation is inhibited by aspirin acutely but this effect does not persist during chronic administration at high doses
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None